Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
Osteoporos Int. 2013 Feb;24(2):567-80. doi: 10.1007/s00198-012-2224-2. Epub 2012 Dec 4.
The Women's Health Initiative (WHI) double-blind, placebo-controlled clinical trial randomly assigned 36,282 postmenopausal women in the U.S. to 1,000 mg elemental calcium carbonate plus 400 IU of vitamin D(3) daily or placebo, with average intervention period of 7.0 years. The trial was designed to test whether calcium plus vitamin D supplementation in a population in which the use of these supplements was widespread would reduce hip fracture, and secondarily, total fracture and colorectal cancer.
This study further examines the health benefits and risks of calcium and vitamin D supplementation using WHI data, with emphasis on fractures, cardiovascular disease, cancer, and total mortality.
WHI calcium and vitamin D randomized clinical trial (CT) data through the end of the intervention period were further analyzed with emphasis on treatment effects in relation to duration of supplementation, and these data were contrasted and combined with corresponding data from the WHI prospective observational study (OS).
Among women not taking personal calcium or vitamin D supplements at baseline, the hazard ratio [HR] for hip fracture occurrence in the CT following 5 or more years of calcium and vitamin D supplementation versus placebo was 0.62 (95 % confidence interval (CI), 0.38-1.00). In combined analyses of CT and OS data, the corresponding HR was 0.65 (95 % CI, 0.44-0.98). Supplementation effects were not apparent on the risks of myocardial infarction, coronary heart disease, total heart disease, stroke, overall cardiovascular disease, colorectal cancer, or total mortality, while evidence for a reduction in breast cancer risk and total invasive cancer risk among calcium plus vitamin D users was only suggestive.
Though based primarily on a subset analysis, long-term use of calcium and vitamin D appears to confer a reduction that may be substantial in the risk of hip fracture among postmenopausal women. Other health benefits and risks of supplementation at doses considered, including an elevation in urinary tract stone formation, appear to be modest and approximately balanced.
妇女健康倡议(WHI)的双盲、安慰剂对照临床试验在美国随机分配了 36282 名绝经后妇女,每天服用 1000 毫克元素碳酸钙加 400 国际单位维生素 D(3)或安慰剂,平均干预期为 7.0 年。该试验旨在测试在广泛使用这些补充剂的人群中,钙加维生素 D 补充剂是否会降低髋部骨折的风险,其次是总骨折和结直肠癌的风险。
本研究进一步利用 WHI 数据研究钙和维生素 D 补充剂的健康益处和风险,重点关注骨折、心血管疾病、癌症和总死亡率。
通过强调补充剂持续时间与治疗效果的关系,进一步分析 WHI 钙和维生素 D 随机临床试验(CT)数据,这些数据与 WHI 前瞻性观察性研究(OS)的数据进行对比和合并。
在基线时未服用个人钙或维生素 D 补充剂的女性中,CT 中服用 5 年或以上钙和维生素 D 补充剂与安慰剂相比,髋部骨折发生的风险比(HR)为 0.62(95%置信区间(CI),0.38-1.00)。在 CT 和 OS 数据的联合分析中,相应的 HR 为 0.65(95%CI,0.44-0.98)。补充剂对心肌梗死、冠心病、总心脏病、中风、整体心血管疾病、结直肠癌或总死亡率的风险没有明显影响,而钙加维生素 D 使用者乳腺癌风险和总侵袭性癌症风险降低的证据仅具有提示性。
尽管主要基于亚组分析,但长期使用钙和维生素 D 似乎可以降低绝经后妇女髋部骨折的风险,这种降低可能是显著的。在考虑的剂量下,补充剂的其他健康益处和风险,包括尿石形成的增加,似乎是适度的,并且大致平衡。